Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

ABP 959 - biosimilar to eculizumab

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

2

ABP 959 - proposed biosimilar to eculizumab

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

3

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[7] 11, 13, 14, 61, 62, 109, 222 💬

Disease ID	Name
11	Myasthenia gravis
13	Multiple sclerosis/Neuromyelitis optica
14	Chronic inflammatory demyelinating polyneuropathy
61	Autoimmune hemolytic anemia
62	Paroxysmal nocturnal hemoglobinuria
109	Atypical hemolytic uremic syndrome
222	Primary nephrotic syndrome

4

SB12 (proposed eculizumab biosimilar)

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

5

Soliris (eculizumab)

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

6

Soliris ™ (eculizumab)

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

7

SOLIRIS® (eculizumab) injection, for intravenous use

[1] Eculizumab (Eculizumab)

[1] Eculizumab (Eculizumab, Eculizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬